Sign In
Buy LTRN
$2.75
+0.140 (+5.36%)
At Close: Aug 04, 2026
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript
03:32pm, Thursday, 30'th Apr 2026
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company advancing precision oncology through its proprietary RADR® AI platform, today announced the expansi
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA)
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN) (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript
01:01pm, Thursday, 09'th Apr 2026
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript
DALLAS--(BUSINESS WIRE)--withZeta.ai is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done.
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript
07:52pm, Monday, 30'th Mar 2026
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
04:05pm, Monday, 30'th Mar 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates.
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
07:23pm, Friday, 27'th Mar 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report.
DALLAS--(BUSINESS WIRE)--Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001.
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
04:30pm, Monday, 23'rd Mar 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET.
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
08:45am, Tuesday, 10'th Feb 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026.
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
08:00am, Tuesday, 20'th Jan 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discove
DALLAS--(BUSINESS WIRE)--A.I. center of excellence - Lantern Pharma.
